selected publications
-
academic article
-
Chia P-LParakh STsao M-SPham N-AGan HKCao DBurvenich IJGRigopoulos AReilly EBJohn TScott AM. Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma.
Pharmaceuticals.
13:289-289.
2020
Full text if available -
Hafeez UParslow ACGan HKScott AM. New insights into ErbB3 function and therapeutic targeting in cancer.
Expert Review of Anticancer Therapy: an essential contribution to decision making in cancer care.
2020
Full text if available -
Lickliter JDGan HKVoskoboynik MArulananda SGao BNagrial AGrimison PHarrison MZou JZhang LLuo SLahn MKallender HMannucci ASomma CWoods KBehren AFernandez-Penas PMillward MMeniawy T. A first-in-human dose finding study of camrelizumab in patients with advanced or metastatic cancer in Australia.
Drug Design, Development and Therapy.
14:1177-1189.
2020
Full text if available -
Janes PWVail MEGan HKScott AM. Antibody targeting of eph receptors in cancer.
Pharmaceuticals.
13.
2020
Full text if available -
Rosenthal MClement PMCampone MGil-Gil MJDeGroot JChinot OIdbaih AGan HRaizer JWen PYPineda EDonnet VMills DEl-Hashimy MMason W. Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study.
ESMO Open.
5:1-11.
2020
Full text if available -
Jackson JEAnderson NJWada MSchneider MPoulsen MRolfo MFahandej MGan HJoon DLKhoo V. Clinical and dosimetric risk stratification for patients at high-risk of feeding tube use during definitive IMRT for head and neck cancer.
Technical Innovations and Patient Support in Radiation Oncology.
14.
2020
Full text if available -
Desai JGan HBarrow CJameson MAtkinson VHaydon AMillward MBegbie SBrown MMarkman BPatterson WHill AHorvath LNagrial ARichardson GJackson CFriedlander MParente PTran BWang LChen YTang ZHuang WWu JZeng DLuo LSolomon B. Phase I, open-label, dose-escalation/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors.
Journal of Clinical Oncology.
38.
2020
Full text if available -
Segelov EUnderhill CPrenen HKarapetis CJackson CNott LClay TPavlakis NSabesan SHeywood ESteer CLethborg CGan HKYip DKaranth NKarikios DMacIntyre CR. Practical considerations for treating patients with cancer in the COVID-19 pandemic.
Jco Oncology Practice.
16.
2020
Full text if available -
Leimgruber AHickson KLee STGan HKCher LMSachinidis JIO’Keefe GJScott AM. Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse.
European Journal of Nuclear Medicine and Molecular Imaging.
47.
2020
Full text if available -
Anderson MGFalls HDMitten MJOleksijew AVaidya KSBoghaert ERGao WPalma JPCao DChia PLJohn TGan HKScott AMReilly EB. Targeting multiple EGFR expressing tumors with a highly potent tumor-selective antibody drug conjugate.
Molecular Cancer Therapeutics.
19:2117-2125.
2020
Full text if available -
Arnaud-Coffin PMaillet DGan HKStelmes JJYou BDalle SPéron J. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors.
International Journal of Cancer.
145:639-648.
2019
Full text if available -
Lee RCGan HK. BI 853520, a FAK-Simile of Prior FAK Inhibitors?.
Targeted Oncology.
14:39-41.
2019
Full text if available -
Le Saux OFalandry CGan HKYou BFreyer GPéron J. Changes in the use of comprehensive geriatric assessment in clinical trials for older patients with cancer over time.
The Oncologist.
24:1089-1094.
2019
Full text if available -
Gougis PBachelard CMKamal MGan HKBorcoman ETorossian NBieche ILe Tourneau C. Clinical development of molecular targeted therapy in head and neck squamous cell carcinoma.
JNCI Cancer Spectrum.
3.
2019
Full text if available -
Lassman ABRoberts-Rapp LSokolova ISong MPestova EKular RMullen CZha ZLu XGomez EBhathena AMaag DKumthekar PGan HKScott AMGuseva MHolen KDAnsell PJvan den Bent MJ. Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma.
Clinical Cancer Research.
25:3259-3265.
2019
Full text if available -
Tiu CLoh ZGan CLGan HJohn THawkes E. Effect of reasons for screen failure on subsequent treatment outcomes in cancer patients assessed for clinical trials.
Oncology: international journal of cancer research and treatment.
97:270-276.
2019
Full text if available -
Gan HKMillward MJHua YQi CSai YSu WWang JZhang LFrigault MMMorgan SYang LLickliter JD. First-in-human phase I study of the selective MET inhibitor, Savolitinib, in patients with advanced solid tumors: Safety, pharmacokinetics and anti-tumor activity.
Clinical Cancer Research.
25:4924-4932.
2019
Full text if available -
Barthel FPJohnson KCVarn FSMoskalik ADTanner GKocakavuk EAnderson KJAbiola OAldape KAlfaro KDAlpar DAmin SBAshley DMBandopadhayay PBarnholtz-Sloan JSBeroukhim RBock CBrastianos PKBrat DJBrodbelt ARBruns AFBulsara KRChakrabarty AChakravarti AChuang JHClaus EBCochran EJConnelly JCostello JFFinocchiaro GFletcher MNFrench PJGan HKGilbert MRGould PVGrimmer MRIavarone AIsmail AJenkinson MDKhasraw MKim HKouwenhoven MCMLaViolette PSLi MLichter PLigon KLLowman AKMalta TMMazor TMcDonald KLMolinaro AMNam DHNayyar NNg HKNgan CYNiclou SPNiers JMNoushmehr HNoorbakhsh JOrmond DRPark CKPoisson LMRabadan RRadlwimmer BRao GReifenberger GSa JKSchuster MShaw BLShort SCSmitt PASSloan AESmits MSuzuki HTabatabai GVan Meir EGWatts CWeller MWesseling PWesterman BAWidhalm GWoehrer AYung WKAZadeh GHuse JTDe Groot JFStead LFVerhaak RGW. Longitudinal molecular trajectories of diffuse glioma in adults.
Nature.
576:112-120.
2019
Full text if available -
Lassman ABvan den Bent MJGan HKReardon DKumthekar PButowski NLwin ZMikkelson TNabors LBPapadopoulos KPPenas-Prado MSimes JWheeler HWalbert TScott AMGomez ELee H-JRoberts-Rapp LXiong HAnsell PJBain EHolen KDMagg DMerrell R. Safety and efficacy of depatuxizumab mafodotin +
temozolomide in patients with EGFR-amplified,
recurrent glioblastoma: results from an international
phase I multicenter trial.
Neuro-Oncology.
21:106-114.
2019
Full text if available -
Anderson NJJackson JEWada MSchneider MPoulsen MRolfo MFahandej MGan HKhoo V. The changing landscape of head and neck cancer radiotherapy patients: is high-risk, prolonged feeding tube use indicative of on-treatment weight loss?.
Journal of Medical Radiation Sciences.
66:250-258.
2019
Full text if available -
Hafeez UMenon SNguyen BLum CGaughran GPranavan GCher LNowak AKGan HParakh S. Young adults diagnosed with high grade gliomas: Patterns of care, outcomes, and impact on employment.
Journal of Clinical Neuroscience.
68:45-50.
2019
Full text if available -
Ameratunga MMiller DNg WWada MGonzalvo ACher LGan HK. A single-institution prospective evaluation of a neuro-oncology multidisciplinary team meeting.
Journal of Clinical Neuroscience.
56:127-130.
2018
Full text if available -
Zer APond GRRazak ARATirona KGan HKChen EXO’Sullivan BWaldron JGoldstein DPWeinreb IHope AJKim JJChan KKWChan AKSiu LLBernstein LJ. Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer.
JAMA Otolaryngology - Head and Neck Surgery.
144:71-79.
2018
Full text if available -
Phillips ACBoghaert ERVaidya KSFalls HDMitten MJDeVries PJBenatuil LHsieh C-MMeulbroek JAPanchal SCBuchanan FGDurbin KRVoorbach MJReuter DRMudd SRLoberg LIRalston SLCao DGan HKScott AMReilly EB. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
Molecular Cancer Therapeutics.
17:795-805.
2018
Full text if available -
Arulananda SLynam JSem Liew MWada MCher LGan HK. Clinical correlates of severe thrombocytopenia from temozolomide in glioblastoma patients.
Internal Medicine Journal.
48:1206-1214.
2018
Full text if available -
Brastianos PKIppen FMHafeez UGan HK. Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies.
The Oncologist.
23:1063-1075.
2018
Full text if available -
Aldape KAmin SBAshley DMBarnholtz-Sloan JSBates AJBeroukhim RBock CBrat DJClaus EBCostello JFde Groot JFFinocchiaro GFrench PJGan HKGriffith BHerold-Mende CCHorbinski CIavarone AKalkanis SNKarabatsou KKim HKouwenhoven MCMMcDonald KLMiletic HNam D-HKeung Ng HNiclou SPNoushmehr HOrmond DRPoisson LMReifenberger GRoncaroli FSa JKSillevis Smitt PAESmits MSouza CFTabatabai GVan Meir EGVerhaak RGWWatts CWesseling PWoehrer AYung WKAJungk CHau A-Cvan Dyck EWesterman BAYin JAbiola OZeps NGrimmond SBuckland MKhasraw MSulman EPMuscat AMStead L. Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium.
Neuro-Oncology.
20:873-884.
2018
Full text if available -
Burvenich IJGParakh SLee F-TGuo NLiu ZGan HKRigopoulos AO'Keefe GJGong SJGoh YWTochon-Danguy HScott FEKotsuma MHirotani KSenaldi GScott AM. Molecular imaging of T cell co-regulator factor B7-H3 with Zr-89-DS-5573a.
Theranostics.
8:4199-4209.
2018
Full text if available -
Hafeez UGan HKScott AM. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases.
Current Opinion in Pharmacology.
41:114-121.
2018
Full text if available -
Ameratunga MChenard-Poirier MMoreno Candilejo IPedregal MLui ADolling DAversa CGarces AIAng JEBanerji UKaye SGan HDoger BMoreno Vde Bono JLopez J. Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.
European Journal of Cancer.
89:56-63.
2018
Full text if available -
Wann ATully PABarnes EHLwin ZJeffree RDrummond KJGan HKhasraw M. Outcomes after second surgery for recurrent glioblastoma: a retrospective case–control study.
Journal of Neuro-Oncology.
137:409-415.
2018
Full text if available -
Bernstein LJPond GRGan HKTirona KChan KKHope AKim JChen EXSiu LLRazak ARA. Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort.
Head and Neck: journal for the sciences and specialities of the head and neck.
40:2029-2042.
2018
Full text if available -
Anderson NJJackson JESmith JGWada MSchneider MPoulsen MRolfo MFahandej MGan HJoon DLKhoo V. Pretreatment risk stratification of feeding tube use in patients treated with intensity-modulated radiotherapy for head and neck cancer.
Head and Neck: journal for the sciences and specialities of the head and neck.
40:2181-2192.
2018
Full text if available -
Burvenich IJGParakh SParslow ACLee STGan HKScott AM. Receptor occupancy imaging studies in oncology drug development.
American Association of Pharmaceutical Scientists (AAPS) Journal.
20:1-16.
2018
Full text if available -
Gan HKReardon DALassman ABMerrell Rvan den Bent MButowski NLwin ZWheeler HFichtel LScott AMGomez EJFischer JMandich HXiong HLee H-JMunasinghe WPRoberts-Rapp LAAnsell PJHolen KDKumthekar P. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Neuro-Oncology.
20:838-847.
2018
Full text if available -
Gan HKvan den Bent MLassman ABReardon DAScott AM. Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells.
Nature Reviews Clinical Oncology.
14:695-707.
2017
Full text if available -
Le Saux OFalandry CGan HKYou BFreyer GPéron J. Changes in the use of end points in clinical trials for elderly cancer patients over time.
Annals of Oncology.
28:2606-2611.
2017
Full text if available -
Reardon DALassman ABvan den Bent MKumthekar PMerrell RScott AMFichtel LSulman EPGomez EFischer JLee H-JMunasinghe WXiong HMandich HRoberts-Rapp LAnsell PHolen KDGan HK. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma..
Neuro-Oncology.
19:965-975.
2017
Full text if available -
van den Bent MGan HKLassman ABKumthekar PMerrell RButowski NLwin ZMikkelsen TNabors LBPapadopoulos KPPenas-Prado MSimes JWheeler HWalbert TScott AMGomez ELee H-JRoberts-Rapp LXiong HBain EAnsell PJHolen KDMaag DReardon DA. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
Cancer Chemotherapy and Pharmacology.
80:1209-1217.
2017
Full text if available -
Parakh SGan HKParslow ACBurvenich IJGBurgess AWScott AM. Evolution of anti-HER2 therapies for cancer treatment.
Cancer Treatment Reviews.
59:1-21.
2017
Full text if available -
Tamjid BPhan PJohn TMitchell PGan H. Outcomes for patients with synchronous and metachronous primary lung cancer after diagnosis of head and neck cancer.
Head and Neck: journal for the sciences and specialities of the head and neck.
39:1544-1549.
2017
Full text if available -
Soria JCGan HKBlagden SPPlummer RArkenau HTRanson MEvans TRJZalcman GBahleda RHollebecque ALemech CDean EBrown JGibson DPeddareddigari VMurray SNebot NMazumdar JSwartz LAuger KRFleming RASingh RMillward M. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Annals of Oncology.
27:2268-2274.
2016
Full text if available -
Maillet DGan HKBlay JYYou BPéron J. Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.
European Journal of Cancer.
52:26-32.
2016
Full text if available -
Parslow ACParakh SLee F-TGan HKScott AM. Antibody-Drug Conjugates for Cancer Therapy.
Biomedicines.
4:1-17.
2016
Full text if available -
Parakh SParslow ACGan HKScott AM. Antibody-mediated delivery of therapeutics for cancer therapy.
Expert Opinion on Drug Delivery.
13:401-419.
2016
Full text if available -
Gan HKBurgess AWParslow ACScott AM. Dual targeting of EGFR: Ready for prime time?.
Translational Cancer Research.
5:S18-S21.
2016
Full text if available -
Burvenich IJGLee F-TGuo NGan HKRigopoulos AParslow ACO'Keefe GJGong SJTochon-Danguy HRudd SEDormelly PSKotsuma MOhtsuka TSenaldi GScott AM. In vitro and in vivo evaluation of 89Zr-DS-8273a as a theranostic for anti-death receptor 5 therapy.
Theranostics.
6:2225-2234.
2016
Full text if available -
Le Saux OFalandry CGan HKYou BFreyer GPeron J. Inclusion of elderly patients in oncology clinical trials.
Annals of Oncology.
27:1799-1804.
2016
Full text if available -
Lee FTBurvenich IJGGuo NKocovski PTochon-Danguy HAckermann UO'Keefe GJGong SRigopoulos ALiu ZGan HKScott AM. L-Tyrosine Confers Residualizing Properties to a D-Amino Acid-Rich Residualizing Peptide for Radioiodination of Internalizing Antibodies.
Molecular Imaging.
15:1-9.
2016
Full text if available -
Burvenich IJGParakh SGan HKLee F-TGuo NRigopoulos ALee S-TGong SO'Keefe GJTochon-Danguy HKotsuma MHasegawa JSenaldi GScott AM. Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with Zr-89-DS-8895a.
Journal of Nuclear Medicine.
57:974-980.
2016
Full text if available -
Parakh SThursfield VCher LDally MDrummond KMurphy MRosenthal MAGan HK. Recurrent glioblastoma: Current patterns of care in an Australian population.
Journal of Clinical Neuroscience.
24:78-82.
2016
Full text if available -
Maillet DBlay JYYou BRachdi AGan HKPeron J. The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members.
Annals of Oncology.
27:192-198.
2016
Full text if available -
Whittle JRLickliter JDGan HKScott AMSimes JSolomon BJMacDiarmid JABrahmbhatt HRosenthal MA. First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma.
Journal of Clinical Neuroscience.
22:1889-1894.
2015
Full text if available -
Kao YHGan HKZaheer SLam WWCLoke KSHWong WYNg DCEGoh ASW. Gender, Race, and Age at Diagnosis as Risk Factors for Metastasis or Recurrence among 1,657 Thyroid Cancer Patients Treated with Radioiodine across 40 Years in Singapore.
Oncology Research and Treatment.
38:679-682.
2015
Full text if available -
Lee W-IAmeratunga Mdu Plessis JGan H. Hypopharyngeal large cell neuroendocrine carcinoma.
BMJ Case Reports.
2015:bcr2015211908-bcr2015211908.
2015
Full text if available -
Gan HKRosenthal MACher LDally MDrummond KMurphy MThursfield V. Management of glioblastoma in Victoria, Australia (2006-2008).
Journal of Clinical Neuroscience.
22:1462-1466.
2015
Full text if available -
Ciprotti MTebbutt NCLee F-TLee S-TGan HKMcKee DCO'Keefe GJGong SJChong GHopkins WChappell BScott FEBrechbiel MWTse ANJansen MMatsumura MKotsuma MWatanabe RVenhaus RBeckman RAGreenberg JScott AM. Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.
Journal of Clinical Oncology.
33:2609-2616.
2015
Full text if available -
Bylicki OGan HKJoly FMaillet DYou BPéron J. Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy.
Annals of Oncology.
26:231-237.
2015
Full text if available -
Richter SSeah J-APond GRGan HKMackenzie MJHotte SJMukherjee SDMurray NKollmannsberger CHeng DHaider MAHalford RIvy SPMoore MJSridhar SS. Evaluation of second line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first line cediranib.
Canadian Urological Association Journal.
8:398-402.
2014
Full text if available -
Campbell RNLiew MSGan HKCher L. Mistaken identity: Granular cell astrocytoma masquerading as histiocytosis of the central nervous system.
Journal of Clinical Neuroscience.
21:1457-1459.
2014
Full text if available -
Tamjid BCher LWada MKalnins RGan H. Olfactory Neuroblastoma (Esthesioneuroblastoma) following Retro-Orbital Irradiation for Graves' Ophthalmopathy.
JOURNAL OF CASE REPORTS AND STUDIES.
1:1-5.
2014
Full text if available -
Ciprotti MChong GGan HKChan AMurone CMacGregor DLee FTJohns TGHeath JKErnst MBurgess AWScott AM. Quantitative intratumoural microdistribution and kinetics of 131I-huA33 antibody in patients with colorectal carcinoma.
EJNMMI Research.
4:1-10.
2014
Full text if available -
Péron JMaillet DGan HKChen EXYou B. Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: A systematic review.
Journal of Clinical Oncology.
31:3957-3963.
2013
Full text if available -
Chang JHWada MAnderson NJLim Joon DLee STGong SJGunawardana DHSachinidis JO'Keefe GGan HKKhoo VScott AM. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using 18F-FMISO PET: A biological modeling study.
Acta Oncologica.
52:1723-1729.
2013
Full text if available -
Péron JYou BGan HKMaillet DChen EXPond GR. Influence of statistician involvement on reporting of randomized clinical trials in medical oncology.
Anti-Cancer Drugs: international journal on anti-cancer agents.
24:306-309.
2013
Full text if available -
Wong SFMak GRosenthal MACher LGan HK. Local perspective on a rare brain tumour: Adult medulloblastoma.
Internal Medicine Journal.
43:567-572.
2013
Full text if available -
Gan HKCvrljevic ANJohns TG. The epidermal growth factor receptor variant III (EGFRvIII): Where wild things are altered.
The Federation of European Biochemical Societies (FEBS) Journal.
280:5350-5370.
2013
Full text if available -
Boespflug AGan HChen ÉXPond GYou B. Enregistrement et publication du critère d’évaluation principal dans les essais contrôlés randomisés en oncologie.
Bulletin du Cancer.
99:943-952.
2012
Full text if available -
Wong SFGan HKCher L. A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide.
Journal of Clinical Neuroscience.
19:1501-1505.
2012
Full text if available -
Gan HKYou BPond GRChen EX. Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer.
Journal of National Cancer Institute.
104:590-598.
2012
Full text if available -
You BGan HKPond GChen EX. Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review.
Journal of Clinical Oncology.
30:210-216.
2012
Full text if available -
Le Tourneau CGan HKRazak ARAPaoletti X. Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents.
PLoS ONE.
7.
2012
Full text if available -
Péron JPond GRGan HKChen EXAlmufti RMaillet DYou B. Quality of reporting of modern randomized controlled trials in medical oncology: A systematic review.
Journal of National Cancer Institute.
104:982-989.
2012
Full text if available -
Gan HKBurgess AWClayton AHAScott AM. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy.
Cancer Research.
72:2924-2930.
2012
Full text if available -
Pillay VGan HKScott AM. Antibodies in oncology.
New Biotechnology.
28:518-529.
2011
Full text if available -
Gan HKBernstein LJBrown JRingash JVakilha MWang LGoldstein DKim JHope AO'Sullivan BWaldron JAbdul Razak ARChen EXSiu LL. Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancer.
International Journal of Radiation: Oncology - Biology - Physics.
81:126-134.
2011
Full text if available -
Le Tourneau CRazak ARAGan HKPop SDiéras VTresca PPaoletti X. Heterogeneity in the definition of dose-limiting toxicity in phase i cancer clinical trials of molecularly targeted agents: A review of the literature.
European Journal of Cancer.
47:1468-1475.
2011
Full text if available -
Le Tourneau CRazak ARALevy CCalugaru VGalatoire ODendale RDesjardins LGan HK. Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland.
British Journal of Ophthalmology.
95:1483-1489.
2011
Full text if available -
Gan HKPond GRMoore MJSiu LL. Reply to D.J. Stewart.
Journal of Clinical Oncology.
28:e651-e651.
2010
Full text if available -
Johns TGMcKay MJCvrljevic ANGan HKTaylor CXu HSmyth FEScott AM. MAb 806 Enhances the Efficacy of Ionizing Radiation in Glioma Xenografts Expressing the de2-7 Epidermal Growth Factor Receptor.
International Journal of Radiation: Oncology - Biology - Physics.
78:572-578.
2010
Full text if available -
Lee FTO'Keefe GJGan HKMountain AJJones GRSaunder THSagona JRigopoulos ASmyth FEJohns TGGovindan SVGoldenberg DMOld LJScott AM. Immuno-PET Quantitation of de2-7 Epidermal Growth Factor Receptor Expression in Glioma Using 124I-IMP-R4-Labeled Antibody ch806.
Journal of Nuclear Medicine.
51:967-972.
2010
Full text if available -
Gan HKGrothey APond GRMoore MJSiu LLSargent D. Randomized Phase II Trials: Inevitable or Inadvisable?.
Journal of Clinical Oncology.
28:2641-2647.
2010
Full text if available -
Gan HKRosenthal MADowling AKalnins RAlgar EWong NBenson AWoods AMCher L. A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.
Neuro-Oncology.
12:500-507.
2010
Full text if available -
Gan HKAzad ACher LMitchell PLR. Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab.
Neuro-Oncology.
12:212-215.
2010
Full text if available -
Arrondeau JGan HKRazak ARAPaoletti XLe Tourneau C. Development of anti-cancer drugs..
Discovery medicine.
10:355-362.
2010
-
Le Tourneau CMichiels SGan HKSiu LL. Reporting of Time-to-Event End Points and Tracking of Failures in Randomized Trials of Radiotherapy With or Without Any Concomitant Anticancer Agent for Locally Advanced Head and Neck Cancer.
Journal of Clinical Oncology.
27:5965-5971.
2009
Full text if available -
Lwin ZGan HKMason WP. Low-grade oligodendroglioma: current treatments and future hopes.
Expert Review of Anticancer Therapy: an essential contribution to decision making in cancer care.
9:1651-1661.
2009
Full text if available -
Gan HKLappas MCao DXCvrljevdic AScott AMJohns TG. Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-κB and initiates tumour vascular normalization.
Journal of Cell and Molecular Medicine.
13:3993-4001.
2009
Full text if available -
Gan HKSeruga BKnox JJ. Sunitinib in solid tumors.
Expert Opinion on Investigational Drugs.
18:821-834.
2009
Full text if available -
Gan HKKaye AHLuwor RB. The EGFRvIII variant in glioblastoma multiforme.
Journal of Clinical Neuroscience.
16:748-754.
2009
Full text if available -
Garrett TPJBurgess AWGan HKLuwor RBCartwright GWalker FOrchard SGClayton AHANice ECRothacker JCatimel BCavenee WKOld LJStockert ERitter GAdams TEHoyne PAWittrup DChao GCochran JRLuo CLou MHuyton TXu YFairlie WDYao SScott AMJohns TG. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR.
Proceedings of the National Academy of Sciences of USA.
106:5082-5087.
2009
Full text if available -
Ashley DMRiffkin CDLovric MMMikeska TDobrovic AMaxwell JAFriedman HSDrummond KJKaye AHGan HKJohns TGHawkins CJ. Erratum: In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
British Journal of Cancer.
100:1012-1012.
2009
Full text if available -
Gan HKSeruga BKnox JJ. Management of toxicities and optimal dosing of targeted drugs in advanced kidney cancer.
Current Oncology.
16:S54-S61.
2009
Full text if available -
Gan HKSeruga BKnox JJ. Targeted therapies for renal cell carcinoma: more gains from using them again.
Current Oncology.
16:S47-S53.
2009
-
Ashley DMRiffkin CDLovric MMMikeska TDobrovic AMaxwell JAFriedman HSDrummond KJKaye AHGan HKJohns TGHawkins CJ. In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
British Journal of Cancer.
99:294-304.
2008
Full text if available -
Gan HKWalker FBurgess AWRigopoulos AScott AMJohns TG. The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor AG1478 Increases the Formation of Inactive Untethered EGFR Dimers.
Journal of Biological Chemistry.
282:2840-2850.
2007
Full text if available -
Gan HKMitchell PLGalettis PDavis IDCebon Jde Souza PLinks M. A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors.
Cancer Chemotherapy and Pharmacology.
58:157-164.
2006
Full text if available -
Gan HLoveland BE. Mannan-MUC1-Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma.
Clinical Cancer Research.
12:869-877.
2006
Full text if available -
Scott AGan HPerera RM. Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor-Specific Antibody Generates Enhanced Antitumor Activity.
Clinical Cancer Research.
11:6390-6399.
2005
Full text if available -
Panousis CRayzman VMJohns TGRenner CLiu ZCartwright GLee F-TWang DGan HCao DKypridis ASmyth FEBrechbiel MWBurgess AWOld LJScott AM. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR.
British Journal of Cancer.
92:1069-1077.
2005
Full text if available
-
Chia P-LParakh STsao M-SPham N-AGan HKCao DBurvenich IJGRigopoulos AReilly EBJohn TScott AM. Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma.
Pharmaceuticals.
13:289-289.
2020
-
chapter
-
Parakh SKing DGan HKScott AM. Current development of monoclonal antibodies in cancer therapy.
Recent Results in Cancer Research.
1-70.
2020
Full text if available -
Gan HKLee JJSiu LL. Phase II Trials with Anticancer Agents.
141-161.
2011
Full text if available
-
Parakh SKing DGan HKScott AM. Current development of monoclonal antibodies in cancer therapy.
Recent Results in Cancer Research.
1-70.
2020
-
conference paper
-
Ines De La Fuente MColman HRosenthal MAndrew Van Tine BLevaci DWalbert TGan HKVieito MMilhem MMLipford KForsyth SMireille Guichard SMikhailov YSedkov AThomson BFrancis Kelly PMonga V. A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine..
Journal of Clinical Oncology.
2020
-
Smith KMHaire SODong AK-QMarkman BGan HKEkert PGO'Byrne KJMillward MSolomon BJTran BScott CLKee DMcArthur GAFellowes AWeerasuriya RLynch EMartyn MGaff CFox SBDesai J. Evaluating barriers to uptake of comprehensive genomic profiling (CGP) in advanced cancer patients (pts)..
Journal of Clinical Oncology.
2020
-
Balasubramanian AGunjur AHafeez UMenon SCher LParakh SGan HK. Inefficiencies in the phase II to phase III transition as a modifiable factor that is impeding successful drug development for glioblastoma..
Journal of Clinical Oncology.
2020
-
Gao BGoh JMarkman BVoskoboynik MGan HKCoward JPalmieri DSo JMeniawy TChen CXiang XQiu JXu YYang LMillward M. Safety and antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors: Ovarian cancer cohort data.
Annals of Oncology.
2019
-
Markman BTran BGan HPrawira ACoward JJin XLi BWang MXia YDesai JMillward M. A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors.
Journal for ImmunoTherapy of Cancer.
2019
-
Coward JGan HKuo JMillward MRichardson GDeng WMitra SSchmidt MXiang HHorvath LPrawira A. A phase 1 study of FPT155, a first-in-class CD80 extracellular domain-Fc fusion protein, in patients with advanced solid tumors.
Journal for ImmunoTherapy of Cancer.
2019
-
Luo DAbdul-Karim RAzad ABendell JGan HJanku FSen STan TWang JSchechet LBaker LLeveque JMeniawy T. Open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707 as a single agent and in combination with a PD-1 inhibitor in adult subjects with advanced or metastatic solid tumors.
Journal for ImmunoTherapy of Cancer.
2019
-
Lassman APugh SWang TAldape KGan HPreusser MVogelbaum MSulman EWon MZhang PMoazami GMacsai MGilbert MBain EBlot VAnsell PSamanta SKundu MSeidel CDe Vos FHsu SCardona ALombardi GBentsion DPeterson RGedye CLebrun-Frenay CWick ACurran WMehta M. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM).
Neuro-Oncology.
17-17.
2019
-
Balasubramanian AGunjur AParakh SCher LGan H. CLINICAL TRIALS IN GLIOBLASTOMA: LEARNING FROM PREVIOUS EXPERIENCES TOWARDS OPTIMAL DEVELOPMENT OF TRIAL DESIGN.
Neuro-Oncology.
114-114.
2019
-
Gan HCher LInglis PLwin ZLau EAckermann UCoombs NRemen KGuo NLee STGong SPalmer JPathmaraj KO'Keefe GScott FDay BBoyd AThomas PDurrant CScott A. PRELIMINARY FINDINGS OF A PHASE I SAFETY AND BIOIMAGING TRIAL OF KB004 (IFABOTUZUMAB) IN PATIENTS WITH GLIOBLASTOMA.
Neuro-Oncology.
6-6.
2019
-
Koh TLCanet EAmjad SBellomo RTaylor DGan HKMarhoon NLim AOng WLKrishnan VKhor R. Prognostic performance of qSOFA in oncology patients admitted to the emergency department with suspected infection.
Asia Pacific Journal of Clinical Oncology.
63-64.
2019
Full text if available -
Gan HCher LInglis PLwin ZLau EWichmann CAckermann UCoombs NRemen KGuo NLee STGong SPalmer JBPathmaraj KO'Keefe GScott FDay BWBoyd AWThomas PDurrant CScott AM. Abstract CT063: Preliminary findings of a Phase I safety and bioimaging trial of KB004 (ifabotuzumab) in patients with glioblastoma.
Cancer Research.
2019
Full text if available -
Goh JGao BMarkman BGan HVoskoboynik MWu Y-LGuo JZhou QZhao JChen CQiu JXu YYang LMillward M. Abstract CT167: A Phase Ib study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors.
Cancer Research.
2019
Full text if available -
Chia PLCao DGan HKReilly EBPhillips AJohn TScott AM. ABT-806 derived antibody drug conjugates (ADCs) inhibit growth of malignant mesothelioma in-vivo..
Journal of Clinical Oncology.
e14677-e14677.
2019
Full text if available -
Reardon DAKaley TJDietrich JClarke JLDunn GLim MCloughesy TFGan HKPark AJSchwarzenberger PRicciardi TMacri MJRyan AVenhaus RR. Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM)..
Journal of Clinical Oncology.
2032-2032.
2019
Full text if available -
Millward MGan HKJoshua AMKuo JC-YPrawira ARichardson GEBarbee SDInamdar SPPierce KLQureshi MHorvath L. FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors..
Journal of Clinical Oncology.
TPS42-TPS42.
2019
Full text if available -
Desai JMarkman BFriedlander MGan HHorvath LTownsend AMillward MJameson MYen C-JHou M-MHou JWu JLiang LDeva S. Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study.
Cancer Research.
2019
Full text if available -
Voskoboynik MMileshkin LGan HMillward MAu-Yeung GMeniawy TMKichenadasse GZhang KZhang MMu SLickliter JD. Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results.
Annals of Oncology.
2019
-
Smith KO'Haire SDong-Anh K-QMarkman BGan HEkert PGO'Byrne KMilward MSolomon BTran BScott CMcArthur GKee DFellowes AXu HMartyn MLynch ELorgelly PGaff CFox SDesai J. iPREDICT: Incorporating complex profiling of patients to enrol onto molecularly directed cancer therapeutics. Preliminary results of the adult and paediatric.
Asia Pacific Journal of Clinical Oncology.
184-185.
2019
-
Gan H. Novel antibody drug conjugates for high grade gliomas and EGFR-expressing tumours.
Cancer Science.
285-285.
2018
-
Sandhu SHill AGan HFriedlander MVoskoboynik MBarlow PTownsend ASong JZhang YLiang LDesai J. Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study.
Annals of Oncology.
28-28.
2018
-
Verhaak RAldape KAmin SAshley DBarnholtz-Sloan JBates ABeroukhim RBock CBrat DClaus ECostello Jde Groot JFinocchiaro GFrench PGan HGriffith BHerold-Mende CHorbinski CIavarone AKalkanis SKarabatsou KKim HKouwenhoven MMcDonald KMiletic HNam D-HNg HKNiclou SNoushmehr HOrmond DPoisson LReifenberger GRoncaroli FSa JKSmitt PSSmits MSouza CFTabatabai Gvan Meir EWatts CWesseling PWoehrer AYung WKAJungk Cvan Dyck EWesterman BAAbiola OZeps NGrimmond S. MOLECULAR EVOLUTION OF DIFFUSE GLIOMAS AND THE GLIOMA LONGITUDINAL ANALYSIS CONSORTIUM.
Neuro-Oncology.
76-76.
2018
-
Gan HKMurone CWong MFitt GKennedy EMaag DAldape K. Radiologically evident treatment effects in patients with glioblastoma (GBM) and its clinical implications.
Annals of Oncology.
2018
Full text if available -
Lassman ABRoberts-Rapp LHe LLu XZha ZBhathena AAnsell PJGan HKScott AMvan den Bent M. GENOMIC PROFILING IDENTIFIES TUBULIN MUTATIONS THAT MAY PREDICT RESPONSE TO DEPATUXIZUMAB MAFODOTIN IN PATIENTS WITH GLIOBLASTOMA.
Neuro-Oncology.
246-246.
2018
-
Ahluwalia MSDimino CRMansukhani MMMurty VVCanoll PNarita YMuragaki YGan HKMerrell RTVan Den Bent MJZha ZRoberts-Rapp LJiang FGuseva MBain EEOcampo CJAnsell PJLassman AB. Effect of therapeutic pressure on stability of EGFR amplification in glioblastoma..
Journal of Clinical Oncology.
2033-2033.
2018
Full text if available -
Sandhu SKHill AGGan HKFriedlander MVoskoboynik MBarlow PTownsend ARSong JZhang YShen ZQi QDesai J. Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody..
Journal of Clinical Oncology.
445-445.
2018
Full text if available -
Krajewska JRobinson BGKeam BCapdevila JKlochikhin AGan HKapiteijn EElisei RPartyka JBorgman AESchlumberger M. A noninferiority trial of cabozantinib (C) comparing 60mg vs 140mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC).
Annals of Oncology.
647-648.
2018
Full text if available -
Chia PLCao DGan HRigopoulos ARiley EPhillips AJohn TScott A. ABT-806 Derived Antibody Drug Conjugates (ADCs) Inhibit Growth of Malignant Mesothelioma In-Vivo.
Journal of Thoracic Oncology.
S745-S745.
2018
Full text if available -
Chia PLCao DRigopoulos AGan HReilly EPhillips AJohn TScott AM. ABT-806-derived antibody-drug conjugates (ADCs) inhibit growth of malignant mesothelioma in vivo.
Cancer Research.
2018
Full text if available -
Tiu CLoh ZGan CHakanson JGan HJohn THawkes E. Effect of reasons for screen failure (RFSF) on standard of care in cancer patients screened for clinical trials.
Annals of Oncology.
170-171.
2018
Full text if available -
Hansen ABauer TMMoreno VMaio MGroenland SMartin-Liberal JGan HRischin DMillward MOlszanski AJCho DCPaul EBallas MEllis CZhou HYadavilli SShaik JSSchmidt EVHoos AAngevin E. First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1.
Annals of Oncology.
404-404.
2018
Full text if available -
Khasraw MMcDonald KLYip SVerhaak RHeimberger AHall MFisher LBarnes ERosenthal MGedye CHovey EEllingson BMSimes JTongela AWheeler HKoh E-SGan HBack MLwin Z. NUTMEG: A randomised phase II study of nivolumab and temozolomide (TMZ) versus TMZ alone in elderly patients with newly diagnosed glioblastoma (GBM): Trial in progress.
Asia Pacific Journal of Clinical Oncology.
196-197.
2018
Full text if available -
Burvenich IParakh SLee F-TTGuo NYLiu ZGan HRigopoulos AO'Keefe GJGong SJGoh YWScott FKotsuma MHirotani KSenaldi GScott A. PET/MRI with Zr-89-Df-Bz-NCS-Df-DS-5573a as a theranostic approach.
European Journal of Nuclear Medicine and Molecular Imaging.
S639-S640.
2018
Full text if available -
Lassman ARoberts-Rapp LHe LLu Xvan den Bent MPapadopoulos KMerrell RKumthekar PReardon DGomez EFischer JJiang FZha ZBhathena AHolen KAnsell PGan HKScott A. MOLECULAR DETERMINANTS ASSOCIATED WITH RESPONSE AND RESISTANCE TO DEPATUXIZUMAB MAFODOTIN (ABT-414) IN PATIENTS WITH RECURRENT GLIOBLASTOMA.
Neuro-Oncology.
176-177.
2017
-
Reardon DKaley TDietrich JClarke JLDunn GPLim MCloughesy TGan HKPark ASchwarzenberger PRicciardi TMacri MRyan AVenhaus R. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM).
Neuro-Oncology.
28-28.
2017
-
Lickliter JGan HGao BGrimison PZou JKallender HSun KChen XBehren AFernandez-Penas PNagrial AVoskoboynik MWoods KMillward MMeniawy T. A first-in-human study of a novel monoclonal antibody INCSHR01210 directed against programmed cell death protein 1 (PD-1) in patients with advanced or metastatic cancer.
Annals of Oncology.
2017
-
Meniawy TRichardson GTownsend ADesai JGan HFriedlander MHorvath LJameson MBSandhu SWu ZQin ZKang KMarkman B. Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb).
Annals of Oncology.
2017
-
Desai JMillward MChao YGan HVoskoboynik MMarkman BTownsend AAtkinson VZhu ASong JQi QKang ADeva S. Preliminary results from subsets of patients (pts) with advanced gastric cancer (GC) and esophageal carcinoma (EC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb).
Annals of Oncology.
2017
-
Yen C-JMarkman BChao YHill AKang JWang LLi KQi QWu ZGan H. Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC).
Annals of Oncology.
iii54-iii54.
2017
Full text if available -
van den Bent MGan HLassman AKumthekar PButowski NNabors LSimes JMaag DReardon D. EFFICACY OF A NOVEL ANTIBODY-DRUG CONJUGATE (ADC), ABT-414, AS MONOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (EGFRAMP), RECURRENT GLIOBLASTOMA (RGBM).
Neuro-Oncology.
13-14.
2017
-
Lassman AGan HRobert-Rapp LAnsell PMerrell RKumthekar PGomez EHolen KReardon Dvan den Bent M. IDENTIFYING THE CORRECT PATIENT (PT) POPULATION FOR ABT414: BIOMARKER ASSAYS FOR EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) IN PTS WITH GLIOBLASTOMA (GBM).
Neuro-Oncology.
75-75.
2017
-
Scott FScott AParakh SBurvenich ILee FTGuo NGan HRigopoulos AO'Keefes GGong STochon-Danguy HKotsuma MSenaldi G. Molecular Imaging of T-cell Co-regulator Factor B7-H3 with Zr-89-DS-5573a.
Journal of Nuclear Medicine.
2017
-
Gan HKBurge MSolomon BLee STHolen KDZhang YCiprotti MLee FTMerdan TMunasinghe WFischer JDAnsell PFox GXiong HReilly EBHumerickhouse RScott AM. A PHASE 1 AND BIODISTRIBUTION STUDY OF ABT-806I, AN INDIUM-111 RADIOLABELED CONJUGATE OF THE TUMOR-SPECIFIC ANTI-EGFR ANTIBODY ABT-806.
Internal Medicine Journal.
13-13.
2017
-
Burvenich IParakh SBurvenich JGLee F-TGuo NGan HKRigopoulos AO'Keefe GJGong STochon-Danguy HKotsuma MHirotani KSenaldi GScott AM. MOLECULAR IMAGING OF T-CELL CO-REGULATOR FACTOR B7-H3 WITH 89Zr-DS-5573A.
Internal Medicine Journal.
20-20.
2017
-
Lassman ABVan Den Bent MJGan HKReardon DAKumthekar PButowski NALwin ZMikkelsen TNabors LBPapadopoulos KPPenas-Prado MSimes JWheeler HGomez EJLee H-JRoberts-Rapp LXiong HBain EEMaag DMerrell RT. Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial..
Journal of Clinical Oncology.
2017
Full text if available -
Desai JMarkman BSandhu SKGan HKFriedlander MTran BMeniawy TBoolell VColyer DNorris CAmeratunga MYang JLi KWang LLuo LQin ZMillward M. A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors..
Journal of Clinical Oncology.
3066-3066.
2016
Full text if available -
Van Den Bent MJGan HKLassman ABKumthekar PMerrell RButowski NALwin ZMikkelsen TNabors LBPapadopoulos KPPenas-Prado MSimes JWheeler HGomez EJLee H-JRoberts-Rapp LXiong HBain EEHolen KDReardon DA. Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM)..
Journal of Clinical Oncology.
2542-2542.
2016
Full text if available -
Reardon DAKaley TJDietrich JLim MDunn GPGan HKCloughesy TFClarke JLPark AJMacri MJRyan ARicciardi TReddy VVenhaus RR. Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM)..
Journal of Clinical Oncology.
TPS2080-TPS2080.
2016
Full text if available -
Lickliter JDGan HKMeniawy TYang JWang LLuo LLu NMillward M. A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors..
Journal of Clinical Oncology.
2016
Full text if available -
Macsai MNariani AGan HLassman AMerrell RGomez EMittapalli RXiong HOcampo CHolen KMoazami G. Corneal Toxicity of ABT-414 in Glioblastoma (GBM): Clinical Manifestations, Ophthalmological Findings and Management.
Investigative Ophthalmology and Visual Science.
269-269.
2016
-
van den Bent MGan HLassman AKumthekar PMerrell RButowski NLwin ZMikkelsen TNabors LPapadopoulos KPenas-Prado MSimes JWalbert TScott AGomez ELee H-JRoberts-Rapp LXiong HBain EHolen KMaag DReardon D. Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified (EGFRamp), recurrent glioblastoma (rGBM).
Neuro-Oncology.
vi2-vi2.
2016
Full text if available -
van den Bent MGan HLassman ABKumthekar PButowski NLwin ZNabors LBSimes JHolen KReardon DA. Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).
Neuro-Oncology.
iv44-iv44.
2016
Full text if available -
Lassman ABvan den Bent MGan HReardon DAKumthekar PButowski NLwin ZMikkelsen TNabors LBPapadopoulos KPPenas-Prado MSimes JWheeler HGomez ELee H-JRoberts-Rapp LXiong HBain EHolen KMerrell R. Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM).
Annals of Oncology.
2016
Full text if available -
Tamjid BPhuong PJohn TMitchell PGan H. Outcome of patients with synchronous and metachronous primary lung cancer after diagnosis of head and neck cancer.
Asia Pacific Journal of Clinical Oncology.
132-132.
2016
Full text if available -
Wann ATully PBarnes LLwin ZJeffree LDrummond KGan HKhasraw M. Outcomes of second surgery for recurrent glioblastoma multiforme: a retrospective case control study.
Neuro-Oncology.
192-192.
2016
Full text if available -
Reardon DADietrich JKaley TGan HDunn GPCloughesy TLim MClarke JPark APan LLai DWKarakunnel JRobbins PNarwal RVenhaus R. Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).
Cancer immunology research.
2016
Full text if available -
Reardon DKaley TDietrich JLim MDunn GGan HCloughesy TClarke JPark AMacri MRyan ARicciardi TReddy VVenhaus R. Phase 2 study to evaluate the clinical efficacy and safety of medi4736 (durvalumab [DUR]) in patients with glioblastoma (GBM): results for cohort b (DUR monotherapy), bevacizumab (BEV) naive patients with recurrent GBM.
Neuro-Oncology.
18-18.
2016
Full text if available -
van den Bent MGan HReardon DAPapadopoulos KPMerrell RKumthekar PRoberts-Rapp LHolen KAnsell PLassman AB. Transcriptional profiling to identify determinants associated with response to ABT-414 in patients with glioblastoma.
Neuro-Oncology.
27-28.
2016
Full text if available -
Scott AMAkhurst TLee FCiprotti MDavis IWeickhardt AGan HKocovski PGuo NMurphy DHicks RLee SO'Keefe GGong SHudson P. Phase I Safety and Biodistribution Study of 124I-PEG-AVP0458 Diabody in Patients with TAG-72 Positive Ovarian and Prostate Cancer.
European Journal of Nuclear Medicine and Molecular Imaging.
S122-S122.
2015
-
Scott AMAkhurst TLee F-TCiprotti MDavis IWeickhardt AGan HKocovski PGuo NMileshkin LWilliams SMurphy DHicks RPathmaraj KLee STO'Keefe GGong SOh MWheatcroft MHudson PJ. Phase I safety and biodistribution study of 124I-PEG-AVP0458 diabody in patients with TAG-72 positive ovarian and prostate cancer.
Cancer Research.
2015
Full text if available -
Reardon DADietrich JKaley TJGan HKDunn GPCloughesy TFLim MClarke JLPark AJPan LSLai DWKarakunnel JJRobbins PBNarwal RVenhaus RR. Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM)..
Journal of Clinical Oncology.
TPS2077-TPS2077.
2015
Full text if available -
Scott AMAkhurst TLee F-TCiprotti MDavis IWeickhardt AGan HKocovski PGuo NMileshkin LWilliams SMurphy DHicks RPathmaraj KLee STO'Keefe GJGong STochon-Danguy HPoniger SOh MWheatcroft MHudson PJ. PHASE I SAFETY AND BIODISTRIBUTION STUDY OF 124I-PEG-AVP0458 DIABODY IN PATIENTS WITH TAG-72 POSITIVE OVARIAN AND PROSTATE CANCER.
Internal Medicine Journal.
11-11.
2015
-
Gan HKLickliter JMillward MGu YWeiguo SUQi CMU HFrigault MMorgan SGardner HAAlbiges LPal SKBurris HAChoueiri TK. cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC)..
Journal of Clinical Oncology.
487-487.
2015
Full text if available -
Roberts-Rapp LAnsell PKular RSong MSokolova IGan HPapadopoulos KPLassman ABMerrell RKumthekar PScott AGomez EFischer JBhathena AHolen KLai RReardon Dvan den Bent M. Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM).
Annals of Oncology.
ix8-ix9.
2015
Full text if available -
Van den Bent MJRoberts-Rapp LAnsell PKular RSong MSokolova IGan HPapadopoulos KPLassman ABMerrell RKumthekar PScott AGomez EFischer JBhathena AHolen KLai RReardon D. Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM).
European Journal of Cancer.
S585-S586.
2015
Full text if available -
Lee FTBurvenich IJGGuo NKocovski PTochon-Danguy HAckermann UO'Keefe GJGong SRigopoulos ALiu ZGan HScott A. L‐tyrosine confers greater residualizing properties to a d‐amino acid rich residualizing peptide for radioiodination of internalizing antibodies.
Internal Medicine Journal.
5-6.
2015
Full text if available -
Hua YShen LGan HLickliter JMillward MXu JWang JSai YSu WFrigault MMQi C. Phase I studies of a selective cMet inhibitor AZD6094 (HMPL504/volitinib) in patients with advanced solid tumors.
Cancer Research.
2015
Full text if available -
Gan HKPapadopoulos KPFichtel LLassman ABMerrell RVan Den Bent MJKumthekar PScott AMPedersen MGomez EJFischer JSAmes WXiong HLee H-JMunasinghe WRoberts-Rapp LAnsell PHolen KDLai RReardon DA. Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM).
Journal of Clinical Oncology.
2015
Full text if available -
Gan HKFichtel LLassman ABMerrell RVan Den Bent MJKumthekar PScott AMPedersen MGomez EFischer JAmes WXiang HDudley MWMunasinghe WRoberls-Rapp LAnsell PHolen KDReardon DA. A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).
Journal of Clinical Oncology.
2014
Full text if available -
Gan HKLickliter JMillward MGu YSU WFrigault MQi CMU H. First-in-human phase I study of a selective c-Met inhibitor volitinib (HMP504/AZD6094) in patients with advanced solid tumors..
Journal of Clinical Oncology.
11111-11111.
2014
Full text if available -
Gan HKFichtel LLassman ABMerrell Rvan den Bent MKumthekar PScott AMPedersen MGomez EFischer JAmes WXiong HDudley MMunasinghe WRoberts-Rapp LAnsell PHolen KReardon DA. A PHASE 1 STUDY EVALUATING ABT-414 WITH TEMOZOLOMIDE (TMZ) OR CONCURRENT RADIOTHERAPY (RT) AND TMZ IN GLIOBLASTOMA (GBM).
Neuro-Oncology.
2014
Full text if available -
Gan HFichtel LLassman AMerrell Rvan den Bent MJKumthekar PScott APedersen MGomez EFischer JAmes WXiong HDudley MRoberts-Rapp LAnsell PJHolen KReardon DA. A phase 1 study evaluating ABT-414 with concurrent radiotherapy (RT) and temozolomide (TMZ) in newly diagnosed glioblastoma (GBM).
Annals of Oncology.
2014
Full text if available -
Anderson NJJackson JKhoo VSchneider MRolfo MGan HKaegi KSneyd FLim Joon DWada M. Gross Tumor Volume Size and Oral Cavity Dose Drive Dysphagia in Definitive (Chemo) IMRT for Head and Neck Cancer.
International Journal of Radiation: Oncology - Biology - Physics.
S566-S567.
2014
Full text if available -
Gan HBurge MESolomon BJHolen KDZhang YCiprotti MMerdan TMunasinghe WPedersen MHintzman PFFox GBHumerickhouse RAScott A. A phase I and biodistribution study of ABT-806i, an (111)indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806..
Journal of Clinical Oncology.
2013
Full text if available -
Ciprotti MTebbutt NCLee FTLee STMcKee DCO'Keefe GJGong SJChong GGan HKHopkins WChappell BScott FEBrechbiel MWTse ANJansen MMatsumura MWatanabe RBeckman RAGreenberg JScott AM. A phase I imaging and pharmacodynamic trial of CS-1008 in patients (pts) with metastatic colorectal cancer (mCRC)..
Journal of Clinical Oncology.
2013
-
Peron JMaillet DGan HChen EXYou B. Adherence to CONSORT adverse event reporting guidelines in medical oncology clinical trials, a systematic review.
European Journal of Cancer.
S192-S192.
2013
Full text if available -
Anderson NJJackson JWada MSchneider-Kolsky MRolfo MGan HKaegi KSneyd FLim Joon DKhoo V. Creating Guidelines for Reactive and Prophylactic Enteral Feeding in Definitive (Chemo) IMRT for Head-and-Neck Cancer.
International Journal of Radiation: Oncology - Biology - Physics.
S471-S471.
2013
Full text if available -
Jackson JEWada MLee STGan HPoon AGong SGunawardana DJoon DLHamilton CScott A. Pre‐Radiotherapy [18F]‐Fluoromisonidazole PET Is Predictive of Long Term Local Control and Survival in Head and Neck Cancer.
Internal Medicine Journal.
7-7.
2013
Full text if available -
Soria JCPlummer RRanson MGan HArkenau HTZalcman GBlagden SEvans TRJPeddareddigari VMazumdar JMurray SGibson DFleming RAAuger KMillward M. 610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma.
European Journal of Cancer.
188-188.
2012
Full text if available -
Gan HNebot NSoria JCArkenau HTBlagden SPlummer RRanson MEvans TRJZalcman GPeddareddigari VGibson DMurray SMazumdar JFleming RAuger KMillward M. 613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors.
European Journal of Cancer.
189-189.
2012
Full text if available -
Liew MSMurone CWalkiewicz MMitchell PGan HBarnett SRussell PWright GScott AJohn T. CORRELATION OF WTEGFR ACTIVATION ASSESSED BY MAB806 BINDING AND EGFR KINASE MUTATIONS IN STAGE IIIA N2 NSCLC.
Annals of Oncology.
542-542.
2012
-
Gregory PArumugaswamy ALeung TChan KLAbikhair MKipp DTam CBajel ACher LGan HGrigg ARitchie DOpat S. IMMUNO-CHEMOTHERAPY CONTAINING RITUXIMAB IS ASSOCIATED WITH IMPROVED SURVIVAL IN PRIMARY CNS B CELL LYMPHOMA.
Haematologica: the hematology journal.
94-95.
2012
-
Soria J-CGan HKArkenau H-TBlagden SPPlummer RRanson MEvans TRJZalcman GBahleda RHollebecque ALemech CBrown JPeddareddigari VGRGibson DMurray SCNebot NMazumdar JFleming RAMillward M. Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.
Journal of Clinical Oncology.
2012
-
Razak ARAGan HKPond GRTirona KMChen EXChan KHope AJKim J-HJSiu LLBernstein LJ. Pretreatment neurocognitive function (NCF) status in head and neck cancer (HNC) patients (pts) with comparison to control cohort.
Journal of Clinical Oncology.
2012
-
Peron JPond GGan HGChen EXMaillet DYou B. 1314 POSTER Quality of Reporting of Modern Randomized Controlled Trials in Oncology.
European Journal of Cancer.
S167-S167.
2011
Full text if available -
Richter SGan HKMacKenzie MJHotte SJMukherjee SDKollmannsberger CKIvy SPFernandes KHalford RMassey CWang LMoore MJSridhar SS. Evaluation of second-line response to targeted therapy following progression on first-line cediranib, an oral pan-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), in advanced renal cell carcinoma (RCC)..
Journal of Clinical Oncology.
e15153-e15153.
2011
Full text if available -
Gan HKYou BPond GRChen EX. Expected benefits versus actual outcomes in oncology phase III randomized controlled trials (RCTs)..
Journal of Clinical Oncology.
2562-2562.
2011
Full text if available -
Razak ARASiu LLChan APond GRTirona KMChen EXHope AJRingash JO'Sullivan BWaldron JNChan KGan HKBernstein LJ. Neurocognitive function (NCF) in patients (pts) treated with chemo/bio-radiotherapy (C/B-RT) for head and neck cancers (HNC)..
Journal of Clinical Oncology.
2011
-
Le Tourneau CRazak RAGan HKPop SPaoletti X. Definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents.
Annals of Oncology.
22-22.
2011
-
Tourneau CLRazak ARAGan HKPop SPaoletti X. Abstract 1690: Definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents.
Cancer Research.
2011
Full text if available -
Gan HKYou BPond GRChen EX. Adequacy of data provision and analysis in oncology phase III trials over the past 5 years..
Journal of Clinical Oncology.
6122-6122.
2010
Full text if available -
Bernstein LJGan HKAbdul Razak ARTirona KMRingash JO'Sullivan BWaldron JNHope AJGoldstein DPSiu LL. Cognitive functioning pre- and postradiotherapy (RT), chemoradiotherapy (CRT), or bioradiotherapy (BRT) in patients with locally advanced squamous cell cancer of the head and neck (LA-SCCHN)..
Journal of Clinical Oncology.
e19629-e19629.
2010
Full text if available -
You BGan HKPond GRChen EX. Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials..
Journal of Clinical Oncology.
6031-6031.
2010
Full text if available -
Gan HKBernstein LJBrown JRingash JVakilha MWang LO'Sullivan BWaldron JChen EXSiu LL. Neurocognitive outcomes of head and neck chemoradiotherapy: A pilot study.
Journal of Clinical Oncology.
2009
-
Le Tourneau CMichiels SGan HSiu L. Reporting of endpoints and tracking of failures in randomized trials of radiotherapy or concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer (LA-HNSCC).
Journal of Clinical Oncology.
2009
-
Gan HKCher LBenson ADowling ARosenthal M. A phase II trial of temolozomide in patients with untreated high grade oligodengroglial brain tumours.
Journal of Clinical Oncology.
13005-13005.
2008
Full text if available -
Gan HKBurgess AWWalker FScott AMJohns TG. The epidermal growth factor receptor (EGFR) exists as an inactive dimer conformation that is reactive with mAb 806 and distinct from the "back-to-back" ligated dimer..
Clinical Cancer Research.
8995S-8995S.
2005
-
Ines De La Fuente MColman HRosenthal MAndrew Van Tine BLevaci DWalbert TGan HKVieito MMilhem MMLipford KForsyth SMireille Guichard SMikhailov YSedkov AThomson BFrancis Kelly PMonga V. A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine..
Journal of Clinical Oncology.
2020
-
conference poster
-
Chia PLCao DGan HReilly EPhillips AJohn TScott A. ABT-806 Derived Antibody Drug Conjugates (ADCs) Inhibit Growth of Malignant Mesothelioma In-Vivo.
Journal of Thoracic Oncology.
S759-S759.
2019
Full text if available -
Lee RCGan HMarhoon NPanagiotopoulos SKhor R. Study evaluating the impact of AI software to identify and validate patients for clinical trials.
Asia Pacific Journal of Clinical Oncology.
166-166.
2019
-
Leimgruber AHickson KLee STGan HCher LSachinidis JO'Keefe GScott AM. GLYOXIA: INTEGRATED ANALYSIS OF GLUCOSE METABOLISM AND HYPOXIA WITH F-18-FLUOROMISONIDAZOLE (FMISO) AND 18F-FLUORODEOXYGLUCOSE (FDG) PET IN HIGH GRADE GLIOMA PATIENTS.
Internal Medicine Journal.
26-27.
2012
-
Chia PLCao DGan HReilly EPhillips AJohn TScott A. ABT-806 Derived Antibody Drug Conjugates (ADCs) Inhibit Growth of Malignant Mesothelioma In-Vivo.
Journal of Thoracic Oncology.
S759-S759.
2019
-
letter
-
Parakh SHamid ACher LGan HK. Temozolomide-Associated Liver Fibrosis.
Journal of Clinical Pharmacology.
1448-1449.
2016
Full text if available -
Wong SFMak GRosenthal MACher LGan HK. Author reply.
Internal Medicine Journal.
210-211.
2014
Full text if available
-
Parakh SHamid ACher LGan HK. Temozolomide-Associated Liver Fibrosis.
Journal of Clinical Pharmacology.
1448-1449.
2016
-
other publication
-
Ameratunga MMcArthur GGan HCher L. Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma.
Journal of Clinical Pharmacy and Therapeutics.
357-359.
2016
Full text if available -
Gan H. Local Perspective On A Rare Brain Tumour: Adult Medulloblastoma – Author Reply.
Internal Medicine Journal.
210-211.
2014
-
Ameratunga MMcArthur GGan HCher L. Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma.
Journal of Clinical Pharmacy and Therapeutics.
357-359.
2016
-
abstract
-
Gan HSeow ALau ESze-Ting LAmeratunga MPerchyonok YCao DRigopoulos ALee H-JGomez EMaag DScott A. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414.
Neuro-Oncology.
24-24.
2018
-
Lassman ABvan den Bent MGan HKReardon DAKumthekar PButowski NLwin ZMikkelsen TNabors LBPapadopoulos KPPenas-Prado MSimes JWheeler HGomez ELee H-JRoberts-Rapp LXiong HBain EHolen KMerrell R. Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM).
Annals of Oncology.
vi103-vi103.
2016
Full text if available -
Gong SJO'Keefe GJLee STAkhurst TLee FTDavis IWeickhardt AGan HPathmeraj KHicks RJHudson PJScott AM. DOSIMETRY OF I-124-PEG-AVP0458 DIABODY IN PATIENTS WITH TAG-72 POSITIVE OVARIAN OR PROSTATE CANCER.
Internal Medicine Journal.
40-41.
2015
-
Gan HSeow ALau ESze-Ting LAmeratunga MPerchyonok YCao DRigopoulos ALee H-JGomez EMaag DScott A. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414.
Neuro-Oncology.
24-24.
2018